Asma intermitente y leve
Resumen
Las guías del asma indican claramente el tratamiento a seguir en cada escalón de gravedad y proporcionan las herramientas para medir el control que ayude a variar la medicación según la evolución de la enfermedad.
Sin embargo, y pese a la difusión que han logrado, una gran mayoría de pacientes no alcanza la situación de control y el cumplimiento terapéutico no es el adecuado.
El mal control se relaciona con la gravedad y la complejidad del tratamiento utilizado, siendo sus causas diversas y atribuibles tanto a médicos como a pacientes.
Parece evidente que en los escalones superiores de gravedad haya un alto porcentaje de pacientes no controlados y que, con la introducción de los anticuerpos monoclonales, susciten el máximo interés.
Sin embargo, el mayor número de pacientes se sitúa en los escalones más bajos, donde tampoco son ajenos a la pérdida de control de la enfermedad ni se ven libres de padecer exacerbaciones. En ellos se incluyen los pacientes con síntomas intermitentes donde se debe tomar la decisión de cuando iniciar el tratamiento.
El objetivo del presente trabajo es revisar el estado actual del tratamiento en los escalones iniciales de gravedad del asma, donde también hay novedades en su manejo.
Referencias
Comité ejecutivo de GEMA. Guía Española para el Manejo el Asma GEMA 4.3. Disponible en www.gemasma.com. (Con acceso el 04/05/2018).
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2018. Disponible en: www. ginasthma.org. (Con acceso el 22/04/2018).
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al.; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–44.
Demoly P, Paggiaro P, Plaza V, Bolge SC, Kannan H, Sohier B, et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev. 2009;18:105–12.
Plaza V, López-Viña A, Entrenas LM, Fernández- Rodríguez C, Melero C, Pérez-Llano L, et al. Differences in Adherence and Non-Adherence Behaviour Patterns to Inhaler Devices Between COPD and Asthma Patients. COPD. 2016;13:547–54.
Pavord ID, Beasley R, Agustí A, Anderson GP, Bel E, Brusselle G, et al. After asthma: redefining airways diseases. Lancet. 2018;391:350–400.
Álvarez Gutiérrez FJ. Anticuerpos monoclonales en el asma. Posibilidad de tratamiento “a la carta”. Monogr Arch Bronconeumol. 2015;2:74–82.
Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen J. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46:622–39.
Vignola AM, Chanez P, Campbell AM, Souques F, Lebel B, Enander I, et al. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med. 1998;157:403–9.
Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332–6.
Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma. Thorax. 2002;57:880–4.
Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al.; START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071–6.
Busse WW, Pedersen S, Pauwels RA, Tan WC, Chen YZ, Lamm CJ, et al.; START Investigators Group. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2008;121:1167–74.
Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ,
Jorup C, et al. Should recommendations about starting
inhaled corticosteroid treatment for mild asthma be based
on symptom frequency: a post-hoc efficacy analysis of the
START study. Lancet. 2017;389:157–66.
Papi A, Fabbri LM. Management of patients with early mild
asthma and infrequent symptoms. Lancet. 2017;389:129–
Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri
D, Pozzi E, et al.; BEST Study Group. Rescue use of
beclomethasone and albuterol in a single inhaler for mild
asthma. N Engl J Med. 2007;356:2040–52.
Ko FD, Hui DS. Many patients labelled as having mild
asthma do not have well-controlled asthma. Respirology.
;23:348–9.
Camargos P, Affonso A, Calazans G, Ramalho L,
Ribeiro ML, Jentzsch N, et al. On-demand intermittent
beclomethasone is effective for mild asthma in Brazil. Clin
Transl Allergy. 2018;8:7.
Du W, Zhou L, Ni Y, Yu Y, Wu F, Shi G. Inhaled
corticosteroids improve lung function, airway hyperresponsiveness
and airway inflammation but not symptom
control in patients with mild intermittent asthma: A metaanalysis.
Exp Ther Med. 2017;14:1594–608.
Wang G, Zhang X, Zhang HP, Wang L, Kang Y, Barnes PJ,
et al. Corticosteroid plus β2-agonist in a single inhaler as
reliever therapy in intermittent and mild asthma: a proofof-
concept systematic review and meta-analysis. Respir
Res. 2017;18:203.
O’Byrne PM, FitzGerald JM, Zhong N, Bateman E, Barnes
PJ, Keen C, et al. The SYGMA programme of phase 3 trials
to evaluate the efficacy and safety of budesonide/formoterol
given ‘as needed’ in mild asthma: study protocols for two
randomised controlled trials. Trials. 2017;18:12.
Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical
management of asthma in 1999: The Asthma Insights
and Reality in Europe (AIRE) study. Eur Respir J.
;16:802–7.
Olaguíbel JM, Quirce S, Juliá B, Fernández C, Fortuna
AM, Molina J, et al.; MAGIC Study Group. Measurement
of asthma control according to Global Initiative for
Asthma guidelines: a comparison with the Asthma Control
Questionnaire. Respir Res. 2012;13:50.
Vennera MC, Picado C, Herráez L, Galera J, Casafont J.
Factores asociados con el asma grave no controlada y con
la percepción del control por parte de médicos y pacientes.
Arch Bronconeumol. 2014;50:384–91.
Martínez-Moragón E, Entrenas LM, Plaza V, Quirce S.
Actitudes y barreras en el asma inicialmente no controlada
en España. Estudio Abanico. Rev Clin Esp. 2017;217:60–2.
Vega JM, Badia X, Badiola C, López-Viña A, Olaguíbel JM,
Picado C, et al.; Covalair Investigator Group. Validation of
the Spanish version of the Asthma Control Test (ACT). J
Asthma. 2007;44:867–72.
Kitch BT, Paltiel AD, Kuntz KM, Dockery DW, Schouten
JP, Weiss ST, et al. A single measure of FEV1 is associated
with risk of asthma attacks in long-term follow-up. Chest.
;126:1875–82.
López-Campos JL, Soriano JB, Calle M. Cambios
interregionales en la realización e interpretación de las
espirometrías en España: estudio 3E. Arch Bronconeumol.
;50:475–83.
Boulet LP, Vervloet D, Magar Y, Foster JM. Adherence: the
goal to control asthma. Clin Chest Med. 2012;33:405–17.
Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW,
Lapidus J, et al.; Better Outcomes of Asthma Treatment
(BOAT) Study Group. Shared treatment decision making
improves adherence and outcomes in poorly controlled
asthma. Am J Respir Crit Care Med. 2010;181:566–77.
Montnémery P, Hansson L, Lanke J, Lindholm LH,
Nyberg P, Löfdahl CG, et al. Accuracy of a first diagnosis of
asthma in primary health care. Fam Pract. 2002;19:365–8.
Bel EH. Clinical Practice. Mild asthma. N Engl J Med.
;369:549–57.
Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D,
Pin I, et al.; Therapy and Health Economics Group of
the European Community Respiratory Health Survey.
Asthma control in Europe: a real-world evaluation based
on an international population-based study. J Allergy Clin
Immunol. 2007;120:1360–7.
Kauppi P, Peura S, Salimäki J, Järvenpää S, Linna M,
Haahtela T. Reduced severity and improved control of selfreported
asthma in Finland during 2001-2010. Asia Pac
Allergy. 2015;5:32–9.
Ding B, Small M. Disease Burden of Mild Asthma:
Findings from a Cross-Sectional Real-World Survey. Adv
Ther. 2017;34:1109–27.
Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J
Allergy Clin Immunol. 1998;102:531–8.
Masoli M, Weatherall M, Holt S, Beasley R. Clinical doseresponse
relationship of fluticasone propionate in adults
with asthma. Thorax. 2004;59:16–20.
Boulet LP. Perception of the role and potential side effects
of inhaled corticosteroids among asthmatic patients. Chest.
;113:587–92.
Ducharme FM. Continuous versus intermittent inhaled
corticosteroids for mild persistent asthma in children: not
too much, not too little. Thorax. 2012;67:102–5.
Rodrigo GJ. Daily versus intermittent inhaled corticosteroid
treatment for mild persistent asthma. Curr Opin Allergy
Clin Immunol. 2014;14:186–91.
King V, Nettleton W. Intermittent Inhaled Corticosteroid
Therapy for Mild Persistent Asthma in Children and
Adults. Am Fam Physician. 2016;94:21–2.
Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy
JV, Lazarus SC, et al.; National Heart, Lung, and Blood
Institute’s Asthma Clinical Research Network. Daily
versus as-needed corticosteroids for mild persistent asthma.
N Engl J Med. 2005;352:1519–28.
Rodríguez-Martínez CE, Nino G, Castro-Rodríguez
JA. Cost-utility analysis of daily versus intermittent
inhaled corticosteroids in mild-persistent asthma. Pediatr
Pulmonol. 2015;50:735–46.
Montelukast Combix 10 mg comprimidos recubiertos con
película EFG. Ficha técnica o resumen de las características
del producto. Disponible en: https://www.aemps.gob.
es/cima/pdfs/es/ft/75786/75786_ft.pdf. (Con acceso el
/04/2018).
Accolate 20 mg comprimidos recubiertos. Ficha
técnica o resumen de las características del producto.
Disponible en: https://www.aemps.gob.es/cima/pdfs/es/
ft/62443/FichaTecnica_62443.html.pdf. (Con acceso el
/04/2018).
Chauhan BF, Ducharme FM. Anti-leukotriene agents
compared to inhaled corticosteroids in the management
of recurrent and/or chronic asthma in adults and children.
Cochrane Database Syst Rev. 2012;5:CD002314.
Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims
EJ, Gilbert RF, et al. Leukotriene antagonists as firstline
or add-on asthma-controller therapy. N Engl J Med.
;364:1695–707.
Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy
JV, Fish JE, et al. Comparison of regularly scheduled with
as-needed use of albuterol in mild asthma. N Engl J Med.
;335:841–7.
Atrovent 20 microgramos solución para inhalación
en envase a presión. Ficha técnica o resumen de las
características del producto. Disponible en: https://www.
aemps.gob.es/cima/pdfs/es/ft/54674/54674_ft.pdf. (Con
acceso el 22/04/2018).
Plaza V, López-Viña A, Entrenas LM, Fernández-
Rodríguez C, Melero C, Pérez-Llano L, et al. Differences
in Adherence and Non-Adherence Behaviour Patterns to
Inhaler Devices Between COPD and Asthma Patients.
COPD. 2016;13:547–54.
Johnson KM, FitzGerald JM, Tavakoli H, Chen W,
Sadatsafavi M. Stability of Asthma Symptom Control in
a Longitudinal Study of Mild-Moderate Asthmatics. J
Allergy Clin Immunol Pract. 2017;5:1663–70.
Partridge MR, Van der Molen T, Myrseth SE, Busse
WW. Attitudes and actions of asthma patients on regular
maintenance therapy: the INSPIRE study. BMC Pulm
Med. 2006;6:13.
Tattersfield AE, Postma DS, Barnes PJ, Svensson K,
Bauer CA, O’Byrne PM, et al. Exacerbations of asthma: a
descriptive study of 425 severe exacerbations. The FACET
International Study Group. Am J Respir Crit Care Med.
;160:594–9.
Patel M, Pilcher J, Hancox RJ, Sheahan D, Pritchard A,
Braithwaite I, et al.; SMART Study Group. The use of
β2-agonist therapy before hospital attendance for severe
asthma exacerbations: a post-hoc analysis. NPJ Prim Care
Respir Med. 2015;25:14099.
Ankerst J. Combination inhalers containing inhaled
corticosteroids and long-acting beta2-agonists: improved
clinical efficacy and dosing options in patients with asthma.
J Asthma. 2005;42:715–24.
Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert
L, Centanni S, et al. Efficacy and safety of budesonide/
formoterol single inhaler therapy versus a higher dose of
budesonide in moderate to severe asthma. Curr Med Res
Opin. 2004;20:1403–18.
Devillier P, Fadel R, De Beaumont O. House dust mite
sublingual immunotherapy is safe in patients with mildto-
moderate, persistent asthma: a clinical trial. Allergy.
;71:249–57.
Lin SY, Erekosima N, Kim JM, Ramanathan M, Suárez-
Cuervo C, Chelladurai Y, et al. Sublingual immunotherapy
for the treatment of allergic rhinoconjunctivitis and asthma:
a systematic review. JAMA. 2013;309:1278–88.
Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen
HH, et al. Efficacy of a house dust mite sublingual allergen
immunotherapy tablet in adults with allergic asthma: A
randomized clinical trial. JAMA. 2016;315:1715–25.
Enlaces refback
- No hay ningún enlace refback.